Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Rheumatology (Oxford, England)|March 12, 2004
Safety of tacrolimus in patients with rheumatoid arthritis: long-term experienceD E Yocum, D E Furst, W G Bensen, et al.
Atherosclerosis|June 11, 2018
Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritisC Charles-Schoeman, G B Gugiu, H Ge, et al.
Arthritis and Rheumatism|March 1, 1985
Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosisH J Williams, D E Furst, S L Dahl, et al.
Annals of the Rheumatic Diseases|January 15, 2004
Infliximab in active early rheumatoid arthritisF C Breedveld, P Emery, E Keystone, et al.
Arthritis and Rheumatism|February 14, 2012
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisP A Merkel, N P Silliman, P J Clements, et al.
Annals of the Rheumatic Diseases|October 16, 2002
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|October 14, 2004
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|October 22, 2005
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Rheumatology (Oxford, England)|March 12, 2004
Safety of tacrolimus in patients with rheumatoid arthritis: long-term experienceD E Yocum, D E Furst, W G Bensen, et al.
Atherosclerosis|June 11, 2018
Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritisC Charles-Schoeman, G B Gugiu, H Ge, et al.
Arthritis and Rheumatism|March 1, 1985
Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosisH J Williams, D E Furst, S L Dahl, et al.
Annals of the Rheumatic Diseases|January 15, 2004
Infliximab in active early rheumatoid arthritisF C Breedveld, P Emery, E Keystone, et al.
Arthritis and Rheumatism|February 14, 2012
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisP A Merkel, N P Silliman, P J Clements, et al.
Annals of the Rheumatic Diseases|October 16, 2002
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|October 14, 2004
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|October 22, 2005
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Pageof 26